WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Human Rights Watch accuses Kenyan government of inadequate response to floodingWinter tour in GuizhouChina to launch ShenzhouXinjiang sees tourism rebound in first two monthsChinese authorities to ensure orderly college entrance examLok Sabha elections 2024: Misinformation surges on social media as voters head to voteRefugee Team for Paris Olympics has 36 athletes from 11 countries across 12 sportsCzech central bank cuts a key interest rate again with inflation down and the economy on the mendRoads, trains and planes to be crowded during holidayChampions League is being expanded and EPL teams have failed to take advantage
2.1711s , 6491.046875 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Global Gateway news portal